SkinBioTherapeutics PLC SkinBioTherapeutics involved in new research grant

TIDMSBTX

SkinBioTherapeutics PLC

29 May 2018

SkinBioTherapeutics plc

SkinBioTherapeutics to fulfil industrial partner role in skin health research grant awarded to the University of Manchester

Manchester, UK - 29 May 2018 - SkinBioTherapeutics plc (AIM: SBTX, the 'Company'), a life science company focused on skin health, announces its collaboration as industrial partner in a grant awarded by the Biotechnology and Biological Sciences Research Council (BBSRC) to The University of Manchester (the 'University').

The grant of approximately GBP600k provides the University with non-dilutive funding for up to three years to investigate how ageing affects the skin and in particular, its microbiome. In the gut, it is currently understood that certain fibres can promote the growth of beneficial bacteria (called a 'prebiotic effect') but research is needed to determine how this principle applies to skin health and which molecules could be prebiotic for the skins microbiome.

BBSRC awarded the grant to enable the University to carry out research which could lead to the development of novel ways to improve the health of the skin microbiome during ageing and in turn, support new approaches to prevent age-related skin conditions and promote long-term skin health. Grant applications of this nature are extremely competitive and the award is a strong external validation of the capabilities of both the University and SkinBioTherapeutics.

SkinBioTherapeutics is supporting the programme as the industrial partner to further work in this exciting new area of the skin microbiome. As industrial partner, SkinBioTherapeutics has first refusal on any IP generated by the project. The Company will be well placed to develop any relevant findings with the potential to extend its current portfolio of indications in skin health, anti-infection and repair.

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"We have a long-standing relationship with the University, and I am delighted this will continue through this latest collaboration. It is testament to both teams that we have been successful with such a prestigious award.

"Unlike the gut, virtually nothing is known about possible prebiotics for skin. This study will provide the foundations for developing novel prebiotic treatments for aged skin. This work is very complementary to the work that we have already underway at SkinBioTherapeutics in skin care, anti-infection and repair."

-Ends-

For more information, please contact:

 
 SkinBioTherapeutics plc                 Tel: +44 (0) 
  Dr. Cath O'Neill, CEO                   161 468 2760 
  Doug Quinn, CFO 
 Instinctif Partners (Media Relations)   Tel: +44 (0) 
  Melanie Toyne-Sewell / Deborah          20 7457 2020 
  Bell                                    [e-mail] 
 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAEASSSAEEPEFF

(END) Dow Jones Newswires

May 29, 2018 02:01 ET (06:01 GMT)